Donanemab

Names

[ CAS No. ]:
1931944-80-7

[ Name ]:
Donanemab

Biological Activity

[Description]:

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2].

[Related Catalog]:

Research Areas >> Neurological Disease

[In Vitro]

Donanemab 是一种针对 N 末端焦谷氨酸 Aβ 表位的人源化 IgG1 抗体，该表位仅存在于已建立的斑块中。Donanemab 对该表位具有特异性，并且未显示与其他 Aβ 种类、神经递质或其受体的脱靶结合[2]。

[References]

[1]. Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112.

[2]. Mark A Mintun, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.